-
52-week Open Label Safety-Tolerability Study
NCT07369154 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Snellville
-
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Augusta
-
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Decatur
-
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female)
· Georgia: Savannah
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Georgia: Augusta, Snellville
-
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Georgia: Augusta, Marietta
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Lawrenceville, Stone Mountain
-
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
NCT07424404 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Lawrenceville, Stone Mountain
-
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur, Peachtree Corners
-
Anti-Inflammatory Challenge in Schizophrenia
NCT05823532 ·
Phase: Phase 4 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCT06740383 ·
Phase: Not specified ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Georgia: Athens
-
CLOZAPINE Response in Biotype-1
NCT04580134 ·
Phase: Phase 4 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Georgia: Athens
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Augusta
-
Cognitive Training for Emotion Regulation in Psychotic Disorders
NCT04414215 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Georgia: Athens
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
NCT05025605 ·
Phase: Phase 1 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Georgia: Atlanta, Austell, Marietta
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Georgia: Atlanta
-
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur, Snellville
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur, Peachtree Corners
-
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Peachtree Corners
-
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Sandy Springs, Savannah
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Lawrenceville, Savannah
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591 ·
Phase: Phase 4 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964 ·
Phase: Phase 2 ·
Ages: 21 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Snellville
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Decatur
-
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Georgia: Atlanta, Decatur
-
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Georgia: Snellville
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Georgia: Decatur